Am J Health Syst Pharm. 2006;63(24):2466-2472. The rationale for the lack of clinically relevant weight gain with insulin detemir therapy has not yet been established. It may be attributed to ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

Ruby Smart, 15, has been taking Levemir (detemir) insulin since she was diagnosed with type 1 diabetes more than two years ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.